DNER and myelofibrosis: Additionally, oral investigational agent Pelabresib (CPI-0610) is a bromodomain and extra-terminal domain (BET) protein inhibitor undergoing concurrent testing with Ruxolitenib in phase 3 clinical trial for myelofibrosis therapy.